Psilocybin-Assisted Therapy
Psilocybin-Assisted Therapy is a psychedelic-assisted treatment associated with the research programs of Roland Griffiths at Johns Hopkins and Robin Carhart-Harris at Imperial College London, whose landmark trials date from the 2010s. Its core mechanism: psilocybin disrupts default mode network activity; on the standard account the mystical-type experience this can occasion is what produces lasting shifts in perspective and meaning, though whether that experience is necessary to the effect is actively disputed. This catalogue links it to depression, substance use and existential and meaning-making concerns, typically in individual format, short (1-3 doses).
Related condition topics
These links support exploration. They do not establish that Psilocybin-Assisted Therapy is effective or recommended for each condition.
How Psilocybin-Assisted Therapy works
Psilocybin disrupts default mode network activity; on the standard account the mystical-type experience this can occasion is what produces lasting shifts in perspective and meaning, though whether that experience is necessary to the effect is actively disputed
Ontology
Rigid self-referential processing (depression) or compulsive patterns maintained by entrenched neural networks
Therapeutic Voice
"Whatever comes, let it come. Whatever goes, let it go. Trust the process."
View of the Person
A consciousness constrained by rigid self-referential processing, capable of liberation through ego dissolution
Epistemology
Evidence
1 condition assessment available
An overall effectiveness assessment has not been completed. Completed assessments for specific populations appear below.
Condition-specific assessments
Each conclusion applies to the population and use described. These source-based assessments do not certify the full entry or replace expert clinical review.
Existential & Meaning-Making Concerns
Population and scope: Carefully selected adults with a potentially life-threatening cancer diagnosis and anxiety/mood symptoms, receiving psilocybin with substantial preparation, monitored sessions and follow-up support.
Randomized studies
Griffiths et al. (2016) randomized dose order in a crossover study: 56 people were assigned and 51 completed at least one session. Higher-dose treatment favored several mood and existential outcomes compared with the very-low-dose condition, including life meaning and death acceptance. After crossover at five weeks, the six-month observations lacked an unexposed comparison. The small, predominantly White, highly educated sample, expectancy and masking limits, and intensive support restrict generalization. Transient anxiety, psychological distress and blood-pressure increases occurred. This is a trial-design assessment for that supervised research context, not a guideline endorsement or evidence for all meaning-making concerns or unsupervised use.
Source assessment dated
Guidelines and official sources (3)
2 clinical guideline checks · 1 regulatory source check
Read the recommendation and its scope. A source may discuss an approach without recommending it.
- FDA accelerates action on treatments for serious mental illness following Executive Order
Not a treatment recommendation
FDA announced priority vouchers for psilocybin studies in April 2026. This establishes development activity, not approval or psychotherapy endorsement.
Scope: Companies studying psilocybin for TRD and MDD
- Management of Major Depressive Disorder
Recommendation against the stated use
VA/DoD strongly recommends against psilocybin for MDD outside research. This 2022 guideline used evidence through January 2021 and does not review subsequent trials.
Scope: Psilocybin for MDD outside research settings
- Clinical Practice Guideline for Management of PTSD and Acute Stress Disorder
Discussed in the source
VA/DoD finds insufficient evidence for or against psilocybin for PTSD. The statement does not separately establish a psychotherapy-protocol recommendation.
Scope: Psilocybin pharmacotherapy for adult PTSD; evidence reviewed through May 2022.
Recorded material under review
The existing notes below are retained separately from assessment records. These recorded claims await source checking, including study design, recommendations and numerical estimates.
10+ RCTs
Ko et al. (2022)
Strong preliminary evidence. Goodwin et al. (2022) NEJM trial positive. Regulatory pathway ongoing.
Training and certification
Not yet FDA-approved at federal level. Oregon (Measure 109, operational 2023) and Colorado (Prop 122, implementation in progress) have created state-regulated facilitator pathways with approved training curricula. Multiple pathways exist: (1) state-licensed facilitator (OR/CO) through programs with state-approved curricula, (2) clinical psychedelic therapy training for licensed clinicians (CIIS, IPI, ATMA), (3) research-context training. Some programs serve both states; others are state-specific.
Oregon: OHA-approved training program → state facilitator license. Colorado: DORA Natural Medicine Division → facilitator certification. Clinical: CIIS Certificate in Psychedelic-Assisted Therapies & Research; IPI year-long training. No federal certification pathway.
State facilitator programs: 120–200+ hrs (varies by program), typically including didactic, experiential, practicum, and supervised components. CIIS certificate: multi-semester. IPI: year-long.
Facilitator programs: $5K–15K+ depending on program. CIIS: graduate tuition rates. State licensing fees additional.
Find a trained therapist
Clinical cautions and blind spots
Assessment and precautions
Active psychosis or personal/family history of psychotic disorders, severe cardiovascular conditions, pregnancy, current use of lithium or tramadol, untreated bipolar I disorder, severe personality disorders with poor reality testing
Blind spots
Not FDA approved; challenging experiences can be destabilizing; standardization of therapy component still developing
Philosophical roots
James (mystical experience); Huxley (doors of perception, reducing valve theory); Watts (ego dissolution); Buddhist concepts (non-self, interconnection); Carhart-Harris (entropic brain hypothesis)
Compared with other approaches
Controversies
Blinding is effectively impossible, so expectancy is built into every result. Two further arguments are unresolved: whether the mystical-type experience is the active ingredient or a side effect, and whether the therapy component contributes anything measurable. Commercialization has also outpaced safety infrastructure, with reports of therapist sexual abuse in both clinical trials and underground settings.
Psilocybin-assisted therapy has not received FDA approval. While it holds Breakthrough Therapy designation and multiple Phase 2 trials show promising results for treatment-resistant depression, the therapy component remains unstandardized: there is no consensus on how many sessions, what kind of preparation, what the therapist does during the experience, or how integration should proceed. The FDA's 2024 rejection of MDMA-assisted therapy on methodological grounds raised concerns about whether psychedelic-assisted therapies can meet regulatory standards given the challenges of blinding and expectancy effects.
Researchers note that the evidence base is growing rapidly and that standardization efforts are underway. The Breakthrough Therapy designation reflects the FDA's recognition of preliminary efficacy. Proponents argue that the regulatory framework developed for pharmaceutical drugs may need adaptation for therapies that combine a substance with a psychotherapeutic process.
The rapid commercialization of psychedelic therapy has outpaced safety infrastructure. Reports of sexual abuse by therapists during psychedelic sessions have emerged from both clinical trials and underground settings: the altered state creates extreme vulnerability and power asymmetry. Training standards for psychedelic therapists are not established. The field has attracted significant venture capital investment, creating financial incentives to minimize safety concerns and accelerate access. Oregon's regulated psilocybin program launched without requiring participants to have a clinical diagnosis.
Professional organizations including MAPS and the Psychedelic Medicine Association have developed ethical guidelines. Advocates argue that regulation through frameworks like Oregon's is safer than unregulated underground use. The field is actively developing safety protocols, including requirements for co-therapist teams and video recording of sessions.
Psilocybin-Assisted Therapy in 1 Comparative Clinical Vignette
Each vignette presents the same client through multiple theoretical lenses side by side — showing how Psilocybin-Assisted Therapy formulates presenting problems, sets treatment focus, and sounds in the consulting room compared with other approaches. This comparative pedagogy is unique to Epoché Clinical; no other clinical reference systematically formulates the same case across traditions.
Test Yourself
Default mode network and psilocybin?
Show answer
DMN active in self-referential thinking. Psilocybin disrupts it, loosening rigid self-narratives.